{"nctId":"NCT00358215","briefTitle":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","startDateStruct":{"date":"2006-06-01","type":"ACTUAL"},"conditions":["Heart Failure","Anemia","Cardiovascular Disease","Ventricular Dysfunction","Congestive Heart Failure"],"count":2278,"armGroups":[{"label":"Darbepoetin alfa","type":"EXPERIMENTAL","interventionNames":["Drug: Darbepoetin alfa"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Darbepoetin alfa","otherNames":["Aranesp®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Heart failure of at least 3 months duration and of New York Heart Association (NYHA) class II, III, or IV\n* hemoglobin between 9.0 g/dL and 12.0 g/dL\n* left ventricular ejection fraction equal to or less than 40%\n\nExclusion Criteria:\n\n* Transferrin saturation (Tsat) \\< 15%\n* Blood pressure \\> 160/100 mm Hg\n* Heart failure primarily due to valvular heart disease or clinically significant valvular heart disease that might lead to surgical correction within 12 months of randomization\n* Recipient of a major organ transplant or receiving renal replacement therapy\n* Serum creatinine \\> 3.0 mg/dL (\\> 265 µmol/L)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to All Cause Death or First Hospitalization for Worsening Heart Failure","description":"Time to death from any cause or first hospital admission for worsening heart failure (adjudicated by the Clinical Endpoint Committee), whichever occurred first, estimated by Kaplan-Meier method. Participants not experiencing a qualifying event during the study were censored at their last contact time or the study termination date, whichever occurred first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1260.0","spread":null},{"groupId":"OG001","value":"1184.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Death From Any Cause","description":"Time from randomization to death due to any cause, estimated by the Kaplan-Meier method. Participants not experiencing a qualifying event during the study were censored at their last contact time or the study termination date, whichever occurred first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1637.0","spread":null},{"groupId":"OG001","value":"1629.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Cardiovascular Death or First Hospital Admission for Worsening Heart Failure","description":"Time to cardiovascular death or first hospital admission for worsening heart failure, whichever occured first, estimated using the Kaplan Meier method. Participants not experiencing a qualifying event during the study were censored at their last contact time or the study termination date, whichever occurred first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1414.0","spread":null},{"groupId":"OG001","value":"1395.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 6 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score","description":"The KCCQ is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life). Least squares means were calculated from a mixed effects model estimating treatment effect adjusted for region, type of device, and Baseline KCCQ score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.48","spread":"0.68"},{"groupId":"OG001","value":"6.68","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 6 in KCCQ Symptom Frequency Score","description":"The KCCQ is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life). Least squares means were calculated from a mixed effects model estimating treatment effect adjusted for region, type of device, and Baseline KCCQ score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.91","spread":"0.76"},{"groupId":"OG001","value":"6.20","spread":"0.76"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":741,"n":1140},"commonTop":["Dyspnoea","Diarrhoea","Dizziness","Cough","Oedema peripheral"]}}}